The Utah Jazz are back to the grind on Tuesday night, facing off against the Memphis Grizzlies for their fifth of a six-game home stint.

Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

Plus: JetBlue CEO eyes more growth in Boston; AG Andrea Campbell offers fiery words about Trump; Charles River chamber offers ...

The biotech company plans to move into the new development in 2028, consolidating other leased and owned spaces in the ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

Through this agreement, Allarity will monitor potential trading abuses, detect unusual short-selling patterns, and ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025ORX750 Phase 2a ...

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...